Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price11.67 USD
Fair value15.00
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markup5.24+122.7% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
AbCellera Biologics Inc. holds its Markup at $11.67. Elevated stress, defensive posture warranted, held for 17 days.
As held on the ledger · 2026-09-16
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 17 days
Price at the screen
$11.67
Valuation
N/A trailing · -16.32 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.32
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.55%
Below 33%
Interest-bearing debt is just 10.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
29.87%
Below 33%
Cash held in interest-bearing accounts and securities is 29.9% of assets, under the one-third limit.
Pass
Receivables
13.77%
Below 49%
Money owed to the company is 13.8% of assets, under the 49% limit.
Pass
Revenue purity
37.71%
Below 5%
37.7% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. A 28.5% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +29% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Antibody platform still deep in the red
Every patient hoping for a new antibody therapy understands the years of trial work before any medicine reaches the clinic. AbCellera has built a discovery engine that delivered 96 percent revenue growth, yet it still posts a negative 182 percent profit margin and negative 15 percent return on equity. We pass because an unknown moat and a negative forward earnings multiple leave too little evidence that the platform converts early promise into durable profits.
The shares sit well below our fair value estimate and analysts rate the stock strongly, but those views rest on future milestones that remain unproven. Ethical screens clear without issue.
Development risk sits at the centre here, with a single Phase 2 asset in vasomotor symptoms and heavy cash burn likely ahead in a capital intensive sector. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Canada and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABCL trades on Nasdaq (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-19Markup$11.67+12.7%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (7 analysts) rates it strong buy, with a mean price target of $10.
2026-08-20Markup$10.36+60.2%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 60.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (7 analysts) rates it strong buy, with a mean price target of $10.
2026-07-20Markup$6.47+23.4%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 23.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (7 analysts) rates it strong buy, with a mean price target of $10.
2026-07-18Markup$5.24+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (7 analysts) rates it strong buy, with a mean price target of $10.
2026-07-16Markup$5.24+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 70%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (7 analysts) rates it strong buy, with a mean price target of $10.
2026-07-03Markup$5.24+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$5.24Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
